Xodus Medical v. Eagle Health LLC: Surgical Positioning Patent Suit Dismissed With Prejudice
Xodus Medical asserted three patents covering Trendelenburg surgical positioning pads against Eagle Health LLC’s Talon Pad and Eagle 1/Eagle 2 kits. Filed in the Eastern District of Tennessee, the case ended in a voluntary dismissal with prejudice just 99 days after filing — with each party bearing its own costs.
Three Surgical Positioning Patents, One Swift Exit: Xodus v. Eagle Health
On June 19, 2025, Xodus Medical, Inc. filed suit against Eagle Health LLC in the United States District Court for the Eastern District of Tennessee (Case No. 3:25-cv-00285), asserting infringement of three patents — US8511314B2, US8464720B1, and US9161876B2 — all directed to Trendelenburg surgical positioning technology. The accused products were Eagle Health’s Talon Pad and two Trendelenburg positioning kits, the Eagle 1 and Eagle 2.
The case closed on September 26, 2025, when Xodus Medical filed a notice of voluntary dismissal with prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(i). Dismissal with prejudice is a final adjudication on the merits for purposes of claim preclusion — Xodus Medical is permanently barred from bringing these same infringement claims against Eagle Health on these three patents. Notably, the parties agreed each side would bear its own costs and attorney fees, suggesting a negotiated resolution rather than a unilateral concession.
At 99 days from filing to closure, the resolution is strikingly fast for a multi-patent infringement action. This timeline — before any substantive court rulings or claim construction proceedings — suggests the parties likely reached a business resolution, potentially including a license or product modification, shortly after the complaint was served. The public record does not disclose the terms of any underlying agreement, and the mutual cost-bearing arrangement is consistent with a negotiated outcome rather than a capitulation by either side.
Filing to Voluntary dismissal in 99 days
99 days — resolved well before the typical 2–3 year district court patent trial timeline
Dismissed with prejudice: what this outcome means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral early exit — but final
A dismissal under Rule 41(a)(1)(A)(i) allows a plaintiff to voluntarily dismiss before the defendant has answered or moved for summary judgment. Filing it ‘with prejudice’ converts what would ordinarily be a no-consequence withdrawal into a final, claim-preclusive judgment. Xodus Medical elected finality — it cannot re-assert these three patents against Eagle Health in a future action.
Claim-preclusive dismissalXodus Medical closes the door permanently on these claims
By dismissing with prejudice, Xodus Medical surrendered its right to sue Eagle Health again on these three patents for the accused Talon Pad and Eagle 1/Eagle 2 products. This is unusual absent a settlement — plaintiffs typically dismiss without prejudice to preserve optionality. The mutual cost-bearing clause and speed of resolution strongly suggest a commercial agreement was reached, making the with-prejudice dismissal a deliberate, negotiated term rather than a concession.
No future claims on these patentsEagle Health obtains permanent protection from these specific claims
Eagle Health LLC achieves a durable litigation shield: Xodus Medical is permanently barred from reasserting US8511314B2, US8464720B1, and US9161876B2 against the Talon Pad and Eagle 1/Eagle 2 kits in this jurisdiction. Without paying costs or fees, Eagle Health avoided a potentially costly claim construction and discovery process. Whether it agreed to modify its products or take a license remains undisclosed.
Permanent bar on reassertionFast resolution signals a negotiated commercial outcome in surgical positioning
A 99-day lifecycle for a three-patent infringement suit — ending with prejudice and mutual cost absorption — is consistent with a confidential license or product-adjustment agreement in the surgical positioning sector. For competitors in the Trendelenburg pad and OR positioning market, these three Xodus Medical patents remain active and enforceable against other parties. The outcome does not resolve questions about claim scope or validity.
Patents remain enforceable vs. othersFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | XODUS MEDICAL | Individual | Surgical patient positioning technology company — holder of US8511314B2, US8464720B1, and US9161876B2Search in Eureka ↗ |
| Defendant | Eagle Health LLC | Company | Eagle Health LLC — maker of Talon Pad and Eagle 1/Eagle 2 Trendelenburg surgical positioning kitsSearch in Eureka ↗ |
| Plaintiff counsel | Anthony W. Brooks | Attorney | Counsel for XODUS MEDICALSearch in Eureka ↗ |
| Plaintiff counsel | Ian Garrett McFarland | Attorney | Counsel for XODUS MEDICALSearch in Eureka ↗ |
| Plaintiff counsel | John T. Winemiller | Attorney | Counsel for XODUS MEDICALSearch in Eureka ↗ |
| Plaintiff counsel | Kent E. Baldauf , Jr. | Attorney | Counsel for XODUS MEDICALSearch in Eureka ↗ |
| Plaintiff counsel | Thomas C. Wolski | Attorney | Counsel for XODUS MEDICALSearch in Eureka ↗ |
| Plaintiff law firm | Merchant & Gould PC (Knox) | Law Firm | Representing XODUS MEDICALSearch in Eureka ↗ |
| Plaintiff law firm | The Webb Law Firm PC | Law Firm | Representing XODUS MEDICALSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Tennessee Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and expressly elects ‘with prejudice’ — language that transforms a procedural exit into a merits-equivalent final judgment under Ninth and Sixth Circuit precedent. The mutual cost-bearing clause is significant: fee-shifting was waived by both sides, which is inconsistent with a unilateral surrender and strongly suggests a negotiated commercial resolution underpinning the filing. No invalidity or non-infringement findings were made; the patents remain presumptively valid and enforceable against third parties.
US8511314B2, US8464720B1 & US9161876B2 — Trendelenburg surgical positioning pad technology
The three asserted patents — US8511314B2, US8464720B1, and US9161876B2 — originate from application numbers filed in 2013 and cover Trendelenburg surgical positioning technology. Trendelenburg positioning involves tilting a patient head-down during surgery, requiring specialised pads and kits to prevent patient migration. The patents collectively span pad construction, anti-slip surface design, and integrated kit configurations. All three are utility patents issued by the USPTO and assigned to Xodus Medical.
For the surgical positioning and OR accessory market, Xodus Medical’s three-patent portfolio represents a meaningful IP barrier. The accused Eagle 1 and Eagle 2 kit products suggest Eagle Health was competing directly in the premium Trendelenburg positioning segment. Any company developing or distributing Trendelenburg pads, shoulder braces, or positioning kits for steep-tilt surgical procedures should treat these three patents as live enforcement risk — particularly given that Xodus Medical demonstrated willingness to litigate with a five-attorney team from Merchant & Gould and The Webb Law Firm.
Should you run an FTO against US8511314B2, US8464720B1, and US9161876B2?
Any manufacturer, distributor, or importer of Trendelenburg surgical positioning pads, anti-slide OR table accessories, or integrated patient positioning kits should treat these three Xodus Medical patents as material FTO risk. The case confirms active enforcement: Xodus Medical retained two experienced IP litigation firms and filed a multi-patent complaint within the current year. The absence of any claim construction ruling means patent scope is at its broadest for FTO purposes.
PatSnap Eureka’s FTO Search Agent can map your product’s features against the independent and dependent claims of all three patents simultaneously, identify prosecution history estoppel that may narrow claim scope, and surface relevant prior art for invalidity analysis. Given that these three patents span overlapping Trendelenburg positioning claim families, a portfolio-level FTO — rather than single-patent analysis — is the appropriate approach for any product in this category.
Run a freedom-to-operate analysis on US8511314B2 to assess your product’s exposure
Run FTO in Eureka →Similar surgical positioning and medical device patent cases in U.S. district courts
Explore patent infringement cases involving surgical positioning technology, OR table accessories, and medical device IP enforced in U.S. district courts.
What this case signals for the surgical positioning IP landscape
A rapid with-prejudice exit across three asserted patents suggests commercial resolution — and active enforcement posture by Xodus Medical.
Xodus Medical’s three-patent portfolio signals an active enforcement strategy
Filing on three separate patents covering Trendelenburg positioning technology signals a broad, layered assertion strategy. Even where one claim might be design-aroundable, multiple patents increase settlement pressure. Competitors in the OR positioning space should map their products against all three patent families, not just the lead patent.
With-prejudice plus mutual costs is the hallmark of a negotiated resolution
When a plaintiff voluntarily dismisses with prejudice and neither party pays costs, the most probable explanation is a confidential licence or design-around agreement. R&D teams at competitors should monitor Eagle Health’s next product generation for any material changes to Trendelenburg pad geometry or anti-slip mechanisms, which may indicate the scope of any agreed modification.
MEDICAL v Eagle — key questions answered
Xodus Medical filed a patent infringement action against Eagle Health LLC in the Eastern District of Tennessee on June 19, 2025, asserting three patents covering Trendelenburg surgical positioning technology against Eagle Health’s Talon Pad and Eagle 1/Eagle 2 kits. The case was voluntarily dismissed with prejudice on September 26, 2025 — 99 days after filing — with each party bearing its own costs and fees.
Xodus Medical asserted US8511314B2 (app. no. US13/773290), US8464720B1 (app. no. US13/737552), and US9161876B2 (app. no. US13/957778) — three utility patents covering Trendelenburg surgical positioning pad and kit technology, all assigned to Xodus Medical.
A dismissal with prejudice operates as a final adjudication on the merits. Xodus Medical is permanently barred from bringing the same infringement claims against Eagle Health LLC on these three patents for the Talon Pad and Eagle 1/Eagle 2 products. The patents, however, remain valid and enforceable against other third parties not party to this dismissal.
The public record does not disclose any settlement agreement. However, the combination of a with-prejudice dismissal, mutual cost-bearing, and a 99-day resolution timeline is strongly consistent with a confidential commercial resolution — such as a licence or design-around agreement — having been reached between the parties before any substantive court proceedings.
The three asserted patents remain active and enforceable against all parties other than Eagle Health LLC. No claim construction or invalidity ruling was issued, so patent scope is unresolved. Companies developing or distributing Trendelenburg pads, anti-slide OR accessories, or surgical positioning kits should conduct a freedom-to-operate analysis against US8511314B2, US8464720B1, and US9161876B2 before commercialising competing products.
PatSnap Eureka searches patents and litigation data to answer instantly.